Nuvation Bio Update

This post is going to cover some near term catalysts for Nuvation Bio, and also illustrate the current oversold condition of the stock, via a couple of charts. 

 

10/23/26:  ESMO Congress Madrid - Eisai presents ROS1 insights ESMO 2026

11/02/26:   First week of November, third quarter financial results

11/12/26:    Society for NeuroOncology - 5 abstracts SNO Conference

01/11/27:    J.P. Morgan Healthcare Conference J.P. Morgan Healthcare

Stocks can trade over-bought at certain levels and over-sold based on chart or valuation measures. Nuvation is currently trading oversold per chart. Some charts below from the close of trading on Friday the 2nd of October. 

The daily chart has had a -29% pullback from a intermediate high of $7.26. RSI which is a relative strength index reading, is in extreme oversold territory at 29.11 per chart. Click to view.

This chart below illustrates how NUVB is trading against it's peers. I'm using the TEMA Oncology ETF symbol CANC as NUVB is one of 59 other oncology companies represented in that ETF. Companies must generate over 50% of their revenues from oncology to be held in the ETF. The CANC currently holds 425K shares of the company. Again, in very oversold condition against it's peers, with an RSI reading of 26.92. 

Disclaimer: This stock, or any other stock referenced on this site, is for educational purposes, not personalized advice. Consult with your investment advisor professional, prior to buying stocks, precious metals, commodity's, or crypto.

Nuvation Bio 2nd Quarter Results

Nuvation Bio (NUVB) is addressing unmet medical need in cancer with lead approved drug Ibtrozi, and clinical testing Safusidenib for high grade glioma. The company released second quarter financial results before market open today. The company is gaining traction with new patients for lead drug Ibtrozi. The drug has been FDA approved for ROS1 NSCLC since June of 2025, and revenues are starting to climb. Some key highlights from the second quarter results below. 

- $31.7 million in second quarter total revenue

- $23.2 Ibtrozi US revenue

- 30% quarter over quarter TKI naive growth

- License and collaboration revenue of $8.5 million

- Convertible senior notes raised $279 million in Q2

- Cash equivalents of $697 million

- Current Market cap of $2.3B

The net loss was $62.8 million for the quarter, or (.18) per share.

Second drug Safusidenib is currently in phase 3 testing with the SIGMA trial for glioma, with expected completion around 2029. The trial can be viewed here NCT05303519. 

All prior Nuvation posts can be viewed here Nuvation Bio Posts. Thank you for reading.

Disclaimer: This stock, or any other stock referenced on this site, is for educational purposes only, not personalized advice. Consult with your investment advisor professional, prior to buying stocks, precious metals, commodity's, or crypto.

NUVB: Nuvation Bio Update #11

All of Nuvation Bio's previous posts, can be found here Nuvation Posts.  The company is addressing the unmet need of ROS1 and high grade glioma, with two unique drugs. 

From recent investor conferences that the company has participated, we were given some updated pipeline information. Two updates of interest, include the following for second drug candidate safusidenib. 

1. The 40 patient Grade 3 oligodendroglioma which is part of the SIGMA study NCT05303519, has objective response rate as the primary endpoint. The goal of achieving a 20% + response rate in this population, would be seen as positive over standard of care chemotherapy for these patients. The study will be conducted as an Open-Label single arm. 

 2. Yet To Be Announced: Safusidenib treatment for those patients that have been on approved drug vorasidenib, and over time have failed. The endpoint again would be objective response rate, with a goal of achieving 20%. 

 

Both trials could benefit from ORR as a quicker endpoint read-out, a smaller number of patients, with potential 2027 data. The daily chart of Nuvation below displays a consolidation range over the past two and a half months. The high of $5.29 and low support at $4.05. This consolidation chart pattern has the potential to have a strong breakout.  

Disclaimer: This stock, or any other stock referenced on this site, is for educational purposes only, not personalized advice. Consult with your investment advisor professional, prior to buying stocks, precious metals, commodity's, or crypto.

NUVB: Nuvation Bio - Update #9

Nuvation Bio held their 4th quarter conference call today to update investors, on the progress of their cancer drug development programs. Just some key points below, as they will be a multi-year investment, with updates along the way.

• 4th quarter revenue of $41 million, a combination of product and license
• Net loss of $36 million, or 0.11 cents per share with 344 million shares outstanding
• The company is well funded with $529 million in cash and equivalents
• Partner Eisai to file for Ibtrozi ROS1 approval in EU by mid-year 2026
• SIGMA safusidenib 40 patient exploratory cohort, grade 3 oligodendroglioma study with readout expected in 2027
• No revenue guidance announced by the company at this time

The stock has been stable, trading in the $5.00 to $6.00 per share range in the last month, with chart below.  Thank you for reading.

NUVB: Nuvation Bio - Update #8

Nuvation Bio has updated investors with the good news of a European partnership, to sell newly FDA approved and commercialized drug Ibtrozi in Europe and other countries outside of the US, for patients with Ros1 NSCLC. Like many other US based companies, they utilize partnerships outside the US who already have a footprint of sales professionals actively selling similar products in the field. Under this agreement completed today with Eisai, there is upfront, milestones and a royalty kick back to the owner of the product, in this case Nuvation Bio. The selling partner reaps the revenue abroad. A win / win cost effective scenario. Below are the Royalty agreements that are now in place outside of the US for Nuvation Bio (NUVB). 

China: Innovent Biologics 
(Dovbleron) First and second-line approval.

-Milestone payments up to $189 million

-Tiered royalty payments based on annual net sales of Taletrectinib

Europe: Eisai

-60 million upfront 

-170 million milestone payments

-10% to 19% tiered royalty payments from net sales of Taletrectinib

Japan: Nippon Kayaku
-Milestone payments based on domestic sales exceeding certain amounts

-Royalty based on domestic net sales

NUVB: Nuvation Bio - Update #7

Past Nuvation Bio posts can be found in date order, by clicking here Nuvation Bio. 

There are different ways to calculate a stock price target. One way is to use a comparison valuation method. This post considers the current market valuation ($2.932 billion) for Nuvation Bio. 

For comparison valuation; In June of 2022 Bristol Myer Squibb offered 4.1 billion to buy Turning Point Therapeutics for their lead drug candidate Repotrectinib a TKI inhibitor for the same indication that Nuvation has been FDA approved for ROS1 NSCLC, BMS News. 

Their interest was lead drug Repotrectinib for ROS1 NSCLC. At the time Repotrectinib had only completed phase 1/2 testing of the drug, and not FDA approved, until 11/23, then again 6/24 for NTRK gene-fusion positive tumors.

 

If we were to apply the 4.1 billion that Turning Point was acquired for, and relate it to NUVB today, it would calculate out to $4100B / 343m shares outstanding = $11.95 per share price target.

- Keeping in mind that Nuvation's lead drug Ibtrozi has already received FDA approved for ROS1 NSCLC and has a global footprint in place to distribute the drug, something that Turning Point did not have at the time of acquisition by BMS.

- Nuvation has already achieved revenues for newly approved Ibtrozi. 

- This comparison is void of any efficacy discussions of Ibtrozi vs Repotrectinib, which should be viewed in another post altogether.

- Nuvation's second drug candidate Safusidenib has entered pivotal phase 3 testing for another unmet need, in glioma.

 

Comparison's can be tricky, but in this case, I would consider the $11.95 stock price of Nuvation Bio ($4.1 billion valuation) the minimum price target, based on this comparison. Chart below, thank you for reading. 

NUVB: Nuvation Bio

Nuvation Bio, a development-stage oncology company, focuses on the clinical development for the treatment of cancer. The companies lead drug Taletrectinib, an orally available inhibitor is currently being reviewed by the FDA for Advanced ROS1+NSCLC, with a decision date (PDUFA) of June 23rd. 

Financial Statistics: 

• $461 million cash
• Debt - minimal
• 340 million diluted shares outstanding
• 782 million market cap

Intellectual Property:

• Taletrectinib - Expected to expire from 2033 to 2042
• Safusidenib - Expected to expire from 2035 to 2041

Timeline Catalyst:

• Taletrectinib: FDA approval decision June 23, 2025
• Safusidenib: Begin pivotal phase 3 for diffuse IDH1-mutant glioma, 2025